trending Market Intelligence /marketintelligence/en/news-insights/trending/vttrj97yccaqp7b0d9abrq2 content esgSubNav
In This List

IntelGenx prices $10M offering to fund acquisition

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


IntelGenx prices $10M offering to fund acquisition

IntelGenx Technologies Corp. priced an offering of 15,873,016 units at 63 cents each to raise funds for the acquisition of a pharmaceutical consulting firm.

Each unit is made up of a common share and a warrant to purchase an additional stock for 90 cents each.

The Canadian company will use the $10 million raised to buy Laboval Inc., with the rest of the proceeds earmarked for the development of its medicine Montelukast.

The offering is expected to close around March 26.